Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE today and set a price target of $138.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Akash Tewari has given his Buy rating due to a combination of factors tied to BioNTech’s fundamentals and pipeline outlook. Despite a year-over-year revenue decline and guidance that points to modest top-line pressure into 2026, the company continues to outperform consensus expectations and is valued by the market at close to its net cash, which he views as an attractive entry point.
Tewari also highlights that BioNTech has more than fifteen Phase 3 studies that could support multiple product launches in areas such as antibody-drug conjugates and novel immuno-oncology combinations over the next several years. While the planned CEO and CMO transition introduces some uncertainty, he believes that bringing in leadership with strong late-stage development and commercial expertise, coupled with a still-sizable COVID revenue base, can unlock value and justify a higher long-term share price even after a reduced target.
In another report released today, Deutsche Bank also maintained a Buy rating on the stock with a $140.00 price target.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.